

# **Global Non-Small Cell Lung Cancer (NSCLC) Market By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region –Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030.**

<https://marketpublishers.com/r/G4DB1FEB2EC6EN.html>

Date: May 2024

Pages: 168

Price: US\$ 5,000.00 (Single User License)

ID: G4DB1FEB2EC6EN

## **Abstracts**

Global Non-Small Cell Lung Cancer (NSCLC) Market By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region –Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030.

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. NON-SMALL CELL LUNG CANCER (NSCLC)**

- 2.1. Product Overview
- 2.2. Market Definition
- 2.3. Segmentation
- 2.4. Assumptions and Acronyms

### **3. RESEARCH METHODOLOGY**

- 3.1. Research Objectives
- 3.2. Primary Research
- 3.3. Secondary Research
- 3.4. Forecast Model
- 3.5. Market Size Estimation

### **4. AVERAGE PRICING ANALYSIS**

### **5. MARKET DYNAMICS**

- 5.1. Growth Drivers
- 5.2. Restraints
- 5.3. Opportunity
- 5.4. Trends

### **6. CORRELATION & REGRESSION ANALYSIS**

- 6.1. Correlation Matrix
- 6.2. Regression Matrix

### **7. RECENT DEVELOPMENT, POLICIES& REGULATORY LANDSCAPE**

### **8. RISK ANALYSIS**

- 8.1. Demand Risk Analysis
- 8.2. Supply Risk Analysis

## **9. NON-SMALL CELL LUNG CANCER (NSCLC) INDUSTRY ANALYSIS**

### 9.1. Porters Five Forces

- 9.1.1. Threat of New Entrants
- 9.1.2. Bargaining Power of Suppliers
- 9.1.3. Threat of Substitutes
- 9.1.4. Rivalry

### 9.2. PEST Analysis

- 9.2.1. Political
- 9.2.2. Economic
- 9.2.3. Social
- 9.2.4. Technological

## **10. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET**

### 10.1. Market Size & forecast, 2019A-2030F

- 10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

## **11. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: MARKET SEGMENTATION**

### 11.1. By Regions

#### 11.1.1. North America:(U.S. and Canada)

- 11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

#### 11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)

- 11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

#### 11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)

- 11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

#### 11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)

- 11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

#### 11.1.5. The Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)

- 11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

### 11.2. By Histology Market Share (2020-2030F)

- 11.2.1. Large cells carcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.2.2. Adenocarcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%)  
2020-2030F

11.2.3. SCC or Squamous cell, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%)  
2020-2030F

11.3. By Treatment: Market Share (2020-2030F)

11.3.1. Chemotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%)  
2020-2030F

11.3.2. Radiation, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.3.3. Surgery, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

## **12. COMPANY PROFILE**

12.1. Rozlytrek (Entrectinib): Hofmann –La Roche

12.1.1. Company Overview

12.1.2. Company Total Revenue (Financials)

12.1.3. Market Potential

12.1.4. Global Presence

12.1.5. Key Performance Indicators

12.1.6. SWOT Analysis

12.1.7. Product Launch

12.2. Opdivo (Nivolumab): Bristol-Myers Squibb

12.3. Tagrisso (Osimertinib): AstraZeneca

12.4. Vizimpro (Dacomitinib): Pfizer

12.5. Portrazza (Nacitumumab): Eli Lilly and Company

12.6. Imfinzi (Durvalumab): AstraZeneca.

12.7. Vitrakvi (Larotrectinib): Bayer Healthcare

12.8. Other Prominent Players

Consultant Recommendation

\*\*The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

## I would like to order

Product name: Global Non-Small Cell Lung Cancer (NSCLC) Market By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region –Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030.

Product link: <https://marketpublishers.com/r/G4DB1FEB2EC6EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4DB1FEB2EC6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970